Literature DB >> 22102029

Crystallization and preliminary X-ray diffraction analysis of prion protein bound to the Fab fragment of the POM1 antibody.

Pravas Kumar Baral1, Barbara Wieland, Mridula Swayampakula, Magdalini Polymenidou, Adriano Aguzzi, Nat N V Kav, Michael N G James.   

Abstract

Prion diseases are neurodegenerative diseases that are characterized by the conversion of the cellular prion protein PrP(c) to the pathogenic isoform PrP(sc). Several antibodies are known to interact with the cellular prion protein and to inhibit this transition. An antibody Fab fragment, Fab POM1, was produced that recognizes a structural motif of the C-terminal domain of mouse prion protein. To study the mechanism by which Fab POM1 recognizes and binds the prion molecule, the complex between Fab POM1 and the C-terminal domain of mouse prion (residues 120-232) was prepared and crystallized. Crystals of this binary complex belonged to the monoclinic space group C2, with unit-cell parameters a = 83.68, b = 106.9, c = 76.25 Å, β = 95.6°.
© 2011 International Union of Crystallography. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102029      PMCID: PMC3212364          DOI: 10.1107/S1744309111026273

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  10 in total

1.  Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells.

Authors:  Cécile Féraudet; Nathalie Morel; Stéphanie Simon; Hervé Volland; Yveline Frobert; Christophe Créminon; Didier Vilette; Sylvain Lehmann; Jacques Grassi
Journal:  J Biol Chem       Date:  2004-12-23       Impact factor: 5.157

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

Authors:  Anthony R White; Perry Enever; Mourad Tayebi; Rosey Mushens; Jackie Linehan; Sebastian Brandner; David Anstee; John Collinge; Simon Hawke
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

4.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

Review 5.  Molecular biology of prion diseases.

Authors:  S B Prusiner
Journal:  Science       Date:  1991-06-14       Impact factor: 47.728

Review 6.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

7.  On-column purification and refolding of recombinant bovine prion protein: using its octarepeat sequences as a natural affinity tag.

Authors:  Shao-Man Yin; Yi Zheng; Po Tien
Journal:  Protein Expr Purif       Date:  2003-11       Impact factor: 1.650

8.  Crystal structure of human prion protein bound to a therapeutic antibody.

Authors:  S V Antonyuk; C R Trevitt; R W Strange; G S Jackson; D Sangar; M Batchelor; S Cooper; C Fraser; S Jones; T Georgiou; A Khalili-Shirazi; A R Clarke; S S Hasnain; J Collinge
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-09       Impact factor: 11.205

Review 9.  Mammalian prion biology: one century of evolving concepts.

Authors:  Adriano Aguzzi; Magdalini Polymenidou
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

10.  The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes.

Authors:  Magdalini Polymenidou; Rita Moos; Mike Scott; Christina Sigurdson; Yong-Zhong Shi; Bill Yajima; Iva Hafner-Bratkovic; Roman Jerala; Simone Hornemann; Kurt Wuthrich; Anne Bellon; Martin Vey; Graciela Garen; Michael N G James; Nat Kav; Adriano Aguzzi
Journal:  PLoS One       Date:  2008-12-08       Impact factor: 3.240

  10 in total
  5 in total

1.  Crystallization and preliminary X-ray diffraction analysis of two peptides from Alzheimer PHF in complex with the MN423 antibody Fab fragment.

Authors:  Rostislav Skrabana; Ondrej Cehlar; Zuzana Flachbartova; Andrej Kovac; Jozef Sevcik; Michal Novak
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-09-25

Review 2.  Transition of the prion protein from a structured cellular form (PrPC ) to the infectious scrapie agent (PrPSc ).

Authors:  Pravas K Baral; Jiang Yin; Adriano Aguzzi; Michael N G James
Journal:  Protein Sci       Date:  2019-10-25       Impact factor: 6.725

3.  The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein.

Authors:  Tiziana Sonati; Regina R Reimann; Jeppe Falsig; Pravas Kumar Baral; Tracy O'Connor; Simone Hornemann; Sine Yaganoglu; Bei Li; Uli S Herrmann; Barbara Wieland; Mridula Swayampakula; Muhammad Hafizur Rahman; Dipankar Das; Nat Kav; Roland Riek; Pawel P Liberski; Michael N G James; Adriano Aguzzi
Journal:  Nature       Date:  2013-07-31       Impact factor: 49.962

4.  Prion infections and anti-PrP antibodies trigger converging neurotoxic pathways.

Authors:  Uli S Herrmann; Tiziana Sonati; Jeppe Falsig; Regina R Reimann; Paolo Dametto; Tracy O'Connor; Bei Li; Agnes Lau; Simone Hornemann; Silvia Sorce; Uli Wagner; Despina Sanoudou; Adriano Aguzzi
Journal:  PLoS Pathog       Date:  2015-02-24       Impact factor: 6.823

5.  A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity.

Authors:  Marco Bardelli; Karl Frontzek; Luca Simonelli; Simone Hornemann; Mattia Pedotti; Federica Mazzola; Manfredi Carta; Valeria Eckhardt; Rocco D'Antuono; Tommaso Virgilio; Santiago F González; Adriano Aguzzi; Luca Varani
Journal:  PLoS Pathog       Date:  2018-10-01       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.